Korro Bio Closes $91.5 Million Series A Financing to Advance the Next Frontier in RNA Therapeutics
Sep 10, 2020•almost 5 years ago
Amount Raised
$91 Million
Round Type
series a
Description
Korro Bio, Inc. today announced a $91.5 million Series A financing to advance its novel platform for precise, single-base, RNA editing to modulate protein function for therapeutic applications. This financing enables Korro to advance its lead program to IND filing and establish a broad portfolio of innovative RNA editing therapies.
FundzWatch™ Score
69
Medium Activity
Buyer Intent Analysis
Get personalized insights on buying likelihood
Funding Insights
Based on industry dataTech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech